We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BU professor fabricates data in two published experiments

BU professor fabricates data in two published experiments

August 10, 2011
CenterWatch Staff

A cancer researcher and assistant professor at the Boston University School of Medicine Cancer Research Center fabricated data in two papers published in scientific journals, federal authorities announced, according to a report by the Boston Globe.

Sheng Wang, an assistant professor whose research involved molecular biology approaches to understanding cancer, no longer works at BU.  Wang has agreed to retract the two papers and will not be eligible for or involved in federally funded research for two years, according to the finding of research misconduct issued by the Office of Research Integrity of the HHS.

The federal authorities found that Wang engaged in research misconduct in projects supported by two federal grants from the National Cancer Institute. According to the federal finding, Wang fabricated experiments used in six out of seven figures in one paper and six out of eight figures in the other. He is listed as the senior author on both papers, which were published in 2009 and explored the role of a gene that suppresses tumor growth.

The sanctions described in the misconduct findings include Wang’s agreement to exclude himself from receiving funds or working for any US government agency for two years. He is also barred from serving on advisory or peer review committees, or as a consultant for the government’s Public Health Service.

United States Ethics/Regulatory

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing